PCM
AZN icon

Prelude Capital Management’s AstraZeneca AZN Stock Holding History

Prelude Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,160
Closed -$1.39M – 1252
2026
Q1 		$1.39M Buy
+7,160
New +$1.38M 0.11% 229
2022
Q4 		– Sell
-3,686
Closed -$404K – 1328
2022
Q3 		$404K Sell
3,686
-6,929
-65% -$879K 0.01% 738
2022
Q2 		$1.4M Buy
+10,615
New +$1.39M 0.04% 403
2020
Q3 		– Sell
-9,430
Closed -$998K – 1820
2020
Q2 		$998K Buy
+9,430
New +$974K 0.06% 322
2020
Q1 		– Sell
-534
Closed -$53K – 1441
2019
Q4 		$53K Sell
534
-6,019
-92% -$567K ﹤0.01% 1312
2019
Q3 		$584K Buy
6,553
+5,833
+810% +$506K 0.03% 482
2019
Q2 		$59K Sell
720
-11,152
-94% -$874K ﹤0.01% 1071
2019
Q1 		$960K Sell
11,872
-3,866
-25% -$305K 0.05% 340
2018
Q4 		$1.2M Sell
15,738
-131
-0.8% -$10.2K 0.08% 279
2018
Q3 		$1.26M Buy
15,869
+5,443
+52% +$412K 0.07% 309
2018
Q2 		$732K Buy
10,426
+96
+0.9% +$6.91K 0.05% 413
2018
Q1 		$722K Buy
10,330
+9,238
+846% +$640K 0.05% 356
2017
Q4 		$76K Buy
1,092
+237
+28% +$16K 0.01% 854
2017
Q3 		$58K Buy
855
+435
+104% +$27.5K 0.01% 1052
2017
Q2 		$29K Sell
420
-5,513
-93% -$360K ﹤0.01% 1169
2017
Q1 		$370K Buy
+5,933
New +$345K 0.04% 377
2015
Q2 		– Sell
-600
Closed -$41K – 1690
2015
Q1 		$41K Sell
600
-4,200
-88% -$292K 0.01% 1405
2014
Q4 		$338K Hold
4,800
– – 0.05% 450
2014
Q3 		$343K Hold
4,800
– – 0.05% 516
2014
Q2 		$357K Buy
+4,800
New +$347K 0.05% 507

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prelude Capital Management's AZN Position: Q2 2026 in Review

Prelude Capital Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 7,160 shares — an estimated $1.39M sold.

Prelude Capital Management first reported a position in AZN in Q2 2014 and held it in 20 quarters. The position peaked at $1.4M in Q2 2022. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Prelude Capital Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 7,160 AstraZeneca shares in Q2 2026, an estimated $1.39M.
  • Prelude Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 20 quarters.
  • Prelude Capital Management's AstraZeneca position peaked at $1.4M in Q2 2022.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.